• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • MRI Images
  • Sample Access
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Neuronet convenes annual event on European research collaboration in Alzheimer’s disease and beyond

2019-10-25News

Neuronet, a coordination and support action funded by the Innovative Medicines Initiative (IMI), brings together 15 IMI consortium projects working on neurodegenerative disease (such as Alzheimer’s), encompassing over EUR 290 million in research funding.

The Neuronet programme held four parallel sessions as part of the Alzheimer Europe conference on 24 and 25 October. This involved showcasing projects that are working to improve our understanding, diagnosis and treatment of neurodegenerative disease.

The first parallel session was chaired by Lennert Steukers from Janssen. It was entitled “European research collaboration in Alzheimer’s disease and beyond”. The three speakers in this session introduced the work of the IMI on neurodegenerative disease (Elisabetta Vaudano, IMI), presented an overview of the Neuronet project (Carlos Diaz, Synapse Research Partners) and highlighted the importance of meaningful patient and public involvement in IMI research projects (Ana Diaz, Alzheimer Europe).

The second parallel session was chaired by Craig Ritchie, Director of the Centre for Dementia Prevention at Edinburgh University, and was entitled “From risk to dementia: Understanding disease progression and its causes”. In this session, leaders of the ADAPTED (María Eugenia Sáez), PHAGO (Angela Hodges) and AETIONOMY (Martin Hofmann-Apitius) projects presented their work on characterising some of the key molecular drivers of Alzheimer’s disease (AD), such as the ApoE genetic risk factor and the innate immune receptors CD33 and TREM2.

The third parallel session was chaired by Jacoline Bouvy of NICE and was entitled “Improving data access and the development of predictive models”. Four IMI projects were presented in this session: EQIPD (Malcolm Macleod), EMIF (Pieter Jelle Visser), ROADMAP (John Gallacher) and IM2PACT (Dominique Lesuisse.) The EQIPD project is developing a framework for improving research quality, aiming to improve the drug development pipeline, while the EMIF and ROADMAP projects showcased the new platforms and tools they have developed to help researchers visualise and access clinical research data and real-world evidence. This session finished with a presentation on the IM2PACT project, which is working to understand the blood-brain-barrier in health and disease.

The fourth Neuronet session was chaired by José Luis Molinuevo, Neuronet Scientific Coordination Board member, and was entitled “Diagnosis, patient engagement and trials”. AMYPAD (José Luis Molinuevo) and EPAD (Craig Ritchie), two sister projects of the IMI neurodegeneration portfolio, highlighted their achievements in using amyloid-PET scans to diagnose AD (AMYPAD), and in creating clinical trial registries and cohorts of people at risk of developing Alzheimer’s dementia (EPAD). The leader of the MOPEAD (Mercè Boada) project then presented the four patient engagement models that they are currently testing, aiming to improve early patient engagement in clinical trials.  The final Neuronet session was brought to a close with a presentation on the RADAR-AD (Dag Aarsland) project, which is exploring how digital technologies can be used non-invasively to measure the progression of disability associated with AD.

This article was originally posted on: https://www.alzheimer-europe.org/News/EU-projects/Friday-25-October-2019-Neuronet-convenes-annual-event-on-European-research-collaboration-in-Alzheimer-s-disease-and-beyond

 

 

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Edinburgh Dementia Prevention Summer School 2022
2022-06-30
EPAD at AAIC22!
2022-06-30
ADDI NeuroToolKit Data Hackathon
2022-05-17
The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
2022-05-09
First national follow-on study to EPAD LCS launches
2022-04-07
The EPAD genomic data is now available on the Alzheimer’s Disease Workbench
2022-03-10
Latest News
  • Edinburgh Dementia Prevention Summer School 2022
    2022-06-30
  • EPAD at AAIC22!
    2022-06-30
  • ADDI NeuroToolKit Data Hackathon
    2022-05-17
  • The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
    2022-05-09
  • First national follow-on study to EPAD LCS launches
    2022-04-07
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

The @CenDemPrevent Summer School, a 4-day interactive course on #brainhealth, is designed for clinicians, researchers and students. Space is limited, sign up quickly! 🗓️26-29 September 📍Edinburgh For more info, including programme⤵️ ep-ad.org/edinburgh-deme… pic.twitter.com/FSypbvWK4L

reply retweet favorite
12:38 pm · 2022-06-30
Twitter
EPAD
EPAD
@IMI_EPAD

There’s still time to join the @AlzData #NeuroToolKit #Data Hackathon! Registration closes on 24 June! Participants will work with @IMI_EPAD datasets and utilise the tools on the #ADWorkbench. Interested in participating? ➡️alzheimersdata.org/hackathon twitter.com/IMI_EPAD/statu…

reply retweet favorite
7:21 am · 2022-06-22
Twitter
EPAD
EPAD
@IMI_EPAD

Today, colleagues from @AlzData visited @CenDemPrevent to meet with those involved in various programmes including @IMI_EPAD @AD_PREVENT. Many relevant discussions and great catch-up! #BrainHealth #datasharing #collaboration @craig_ritchie68 @samdansobe @GregorySarah @CindyBirck pic.twitter.com/Mr3trKeuoz

reply retweet favorite
2:43 pm · 2022-06-15
Twitter
EPAD
EPAD
@IMI_EPAD

Have a look on the new @AlzheimerEurope #DementiaInEurope magazine featuring an article on @IMI_EPAD and its collaboration with @AlzData to make our data findable, accessible and reusable. @craig_ritchie68 ⤵️ alzheimer-europe.org/resource… twitter.com/AlzheimerEurop… pic.twitter.com/vLuW3HMLUh

reply retweet favorite
1:09 pm · 2022-06-14
Twitter
EPAD
EPAD
@IMI_EPAD

Registration will close tomorrow! Register now for the free #Brainhealth2022 conference, taking place next week in Edinburgh ⤵️ brainhealth.scot/brainhealth2… twitter.com/IMI_EPAD/statu…

reply retweet favorite
3:05 pm · 2022-06-09
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT